-+ 0.00%
-+ 0.00%
-+ 0.00%

On September 17, Kang Fang Biotech announced that its self-developed innovative dual-antibody ADC drug AK158D1 has been approved by the Drug Evaluation Center of the State Drug Administration to conduct phase I clinical studies for the treatment of advanced malignant solid tumors.

Zhitongcaijing·09/17/2026 05:09:06
Listen to the news
On September 17, Kang Fang Biotech announced that its self-developed innovative dual-antibody ADC drug AK158D1 has been approved by the Drug Evaluation Center of the State Drug Administration to conduct phase I clinical studies for the treatment of advanced malignant solid tumors.